Citations

Clear

941 citation(s) found for "Tan, MH".

A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
McKay, Rana R., Atherton, Pamela J. , Ballman, Karla V., Jacene, Heather, Chen, Ronald C., Cole, Suzanne, Baghdadi, Tareq Al, Kwok, Young , Tan, Alan, Berg, S., Beltran, H, Morris, M J, Zhang, Tian, Galsky, Matthew D. , Rosenberg, Jonathan E., George, Daniel J., Choueiri, Toni K., McKay, Rana R. , Ballman, Karla V. , Jacene, Heather A. , Choudhury, Atish D. , Lang, Joshua M. , Cole, Suzanne , Morris, Michael J. , McGregor, Bradley A. , Zhang, T., Rosenberg, Jonathan E , George, Daniel J. , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4500-4500

10.1200/jco.2026.44.16_suppl.4500 Get It

4500 Background: BM occur in ~30% of RCC pts and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, prolongs survival in advanced prostate cancer. A pilot study of radium-223 with VEGF tyrosine kinase inhibitors (TKI) in RCC with BM showed safety and early efficacy (McKay, CCR, 2018). Cabozantinib is a TKI that showed efficacy in BM. RADICAL (NCT04071223) was designed to investigate cabozantinib ± radium-223 in RCC with BM. Methods: This open label multicenter study enrolled RCC pts with ≥1 symptomatic BM not previously irradiated and Karnofsky performance status ≥60%. Prior therapies were allowed; non-clear cell population was limited to 20%. Randomization was 1:1 to cabozantinib with (Arm A) or without (Arm B) radium-223, stratified by osteoclast-targeted therapy (OTT), prior therapy, baseline opioid use, and IMDC risk. In Arm A, cabozantinib was 40 mg daily cycle 1, 60 mg thereafter if tolerated; radium-223 was 1.49 microcurie/kg IV every 28 days for 6 doses. In Arm B, cabozantinib was 60 mg daily. The primary endpoint was SSE-free survival (SSE-FS). Secondary endpoints were safety, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). The study was designed with 85% power to detect improvement in 6-month SSE-FS from 65% to 78% (one-sided α=0.05), with planned interim futility analysis at 50% of expected events. Results: From 12/2019 to 9/2025, 90 pts were enrolled and evaluable for the interim analysis. Median age was 63 years; 74.4% male, 90.0% White, 83.3% clear cell histology. 11.1% were treatment naïve, 80.0% received OTT, 51.1% had baseline opioid use. IMDC risk was 16.7% favorable, 68.9% intermediate, 14.4% poor. Median cabozantinib dose was 31.4 mg (Arm A) and 40.0 mg (Arm B); median radium-223 cycles was 6. Median follow-up was 13.1 (range 0.1-49.4) months with 50 events, 17 SSEs (Arm A: 10; Arm B: 7) and 33 deaths (Arm A: 13; Arm B: 20). Outcomes are in Table. 71 pts were evaluable for response. ORR was 22.2% (Arm A), 22.9% (Arm B). Any grade treatment-related adverse events were 97.7% (Arm A), 93.2% (Arm B); grade ≥3 were 65.9% (Arm A), 56.8% (Arm B). The trial closed after interim analysis as SSE-FS did not meet the prespecified futility boundary (HR≤1). Conclusions: Radium-223 did not improve the primary endpoint of SSE-FS when added to cabozantinib but a numerical prolongation in OS was observed. Combination treatment was safe. Alternative radiotherapeutics warrant investigation in RCC. Clinical trial information: NCT04071223 . Interim efficacy analysis. Arm Median(95% CI) HR (95% CI) Stratified SSE-FS A 17.9 (15.0-NE) 1.24 (0.62-2.48) B 17.6 (10.9-NE) Unstratified SSE-FS A 17.9 (15.0-NE) 0.90 (0.51-1.59) B 17.6 (10.9-NE) OS A 32.2 (17.9-NE) 0.77 (0.42-1.41) B 21.3 (12.3-NE) Stratified PFS A 11.0 (5.8-17.4) 1.39 (0.72-2.66) B 11.2 (9.0-18.5)
Cabozantinib in high-grade neuroendocrine neoplasms.
Trikalinos, Nikolaos, Firwana, Belal, Reimers, Melissa A., Mehan, Paul, Rohatgi, Anjali , Pressey, Olive, Waldron, Nicholas, Wu, Shuang , Tan, Benjamin , Suresh, Rama , Pedersen, Katrina S. , Firwana, Belal , Reimers, Melissa A. , Liu, Jingxia

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4183-4183

10.1200/jco.2026.44.16_suppl.4183 Get It

4183 Background: High grade neuroendocrine neoplasms (HG-NENs) are treated with platinum doublets mirroring guidelines for small cell lung cancer (SCLC) but recurrences are common and salvage options are limited in efficacy. Cabozantinib (CABO), an inhibitor of VEGFR, MET, and TAM kinases (TYRO3, AXL, and MER) was approved by the FDA for treatment of well differentiated (WD) NENs of both pancreatic and extrapancreatic origins based on the CABINET study (Chan, NEJM 2025). However, its efficacy in the whole spectrum of HG-NEN patients including poorly differentiated disease (PDD) has not been prospectively explored. Methods: This was a single institution, Phase II study of CABO in patients with HG-NENs who had progressed on at least one prior treatment. Key inclusion/exclusion criteria were NENs of any origin except SCLC, high grade by Ki-67 of > 20% or histology consensus, ECOG of < = 1, appropriate hematological parameters and no history of bleeding or active cardiac disease. CABO was given orally starting at 60 mg po daily in 3-week cycles. The primary endpoint of this study was overall response rate (ORR). Secondary endpoints included progression free survival (PFS) and overall survival (OS). A Simon optimal 2-stage design tested the null hypothesis that the true ORR is < = 1% at the type I error rate of 5%, resulting in projected enrollment of up to 32 total patients. Toxicities were graded according to CTCAE v5.0 and response was evaluated according to RECIST v1. Results: All patients have been accrued, with 4/32 patients still on treatment. Median age at diagnosis was 62 years and male to female ratio was 1.46. Origin of tumor was GI in 68.8% of the cases, the rest being thoracic (6.3%), prostate (6.3%) cervical (6.3%) head/neck (3.1%) and unknown (9.4%). Median Ki-67 was 55%, 11 patients had Ki-67 > 70%. Histology was WD-HG in 40% of patients and PDD in 60%. Two patients had mixed PDD/other components (MiNEN). Median PFS in evaluable patients was 4.01 months [95% CI 1.61 to 9.30] and mOS was 9.89 mo [95% CI 6.73 to 18.96]. Three patients so far (9.3%) have had partial response as best response (PDD-colon, WD-pancreas and PDD-cervical) while 19/32 (59.4%) patients have had stable disease as best response so far (disease control rate 68.8%). Five (15.6%) patients have received more than 10 treatment cycles. The three longest treated patients had WD-pancreas (23 and 17 cycles) and PDD-unknown (12 cycles). One patient had eventual resection of a metastatic site and is currently without evidence of disease. Three patients withdrew from the trial because of toxicities (shortness of breath, GI bleeding, thromboembolism). Twenty-six patients have expired. Conclusions: CABO monotherapy showed efficacy in some HG-NEN patients with not just WD but also the very aggressive PDD histology. No new side effects to the ones previously described for this agent were noted. Supported by Exelixis and a Siteman investment program grant. Clinical trial information: NCT04412629 .
Final results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated biliary tract cancer (NAPOLI-2).
Tan, Benjamin R., Turk, Anita, Sung, Max W. , Aranha, Olivia, Mukherji, Reetu , Noel, Marcus Smith , Lim, Kian-Huat, Khushman, M., Trikalinos, Nikolaos, Marshall, John, Wang, Hongkun, Weinberg, Benjamin A. , Tan, Benjamin , He, Aiwu Ruth , Aranha, Olivia , Ratner, Lee , Suresh, Rama , Lim, Kian-Huat, Marshall, John L , Pedersen, Katrina S.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4122-4122

10.1200/jco.2026.44.16_suppl.4122 Get It

4122 Background: BTCs are rare and aggressive malignancies. The first-line standard of care regimen for advanced BTC (aBTC) is gemcitabine (GEM), cisplatin, and an immune checkpoint inhibitor. Although FOLFOX is a preferred second-line treatment, it is limited by neuropathy. Nal-IRI contains IRI free base in liposome nanoparticles, which shelter IRI from conversion to its active metabolite (SN-38) and increase intratumoral SN-38 compared with IRI alone. The NAPOLI-1 trial of FU/LV/nal-IRI vs. FU/LV in second-line advanced pancreatic adenocarcinoma showed an overall survival (OS) benefit. The NIFTY trial (South Korea) demonstrated median OS (mOS) benefit of FU/LV/nal-IRI over FU/LV in a second-line aBTC population (8.6 vs. 5.3 months [mo], HR 0.68, 95% CI 0.48-0.95); however, the NALIRICC trial (Germany) did not (6.9 vs. 8.2 mo, HR 1.08, 95% CI 0.68-1.72). We sought to characterize second-line FU/LV/nal-IRI efficacy in US patients (pts) with second-line aBTC. Methods: This was a single-arm, open-label, multicenter phase II study of pts with aBTC previously treated with GEM/platinum chemotherapy. Pts received nal-IRI 70 mg/m 2 IV over 90 minutes, LV 400 mg/m 2 IV over 30 minutes every 14 days, and FU 2400 mg/m 2 IV over 46 hours every 14 days. The primary objective was to determine progression-free survival rate at 4 mo (PFS 4mo ) using RECIST v. 1.1 criteria. Median PFS reported for pts receiving second-line 5-FU doublet chemotherapy was 3 mo with a PFS of 30%. FU/LV/nal-IRI was of interest if it could increase the PFS 4mo to 50% or higher. Using a one-sided α of 0.05 and 80% power, 17 of 39 evaluable pts had to be progression-free at 4 mo to detect a difference in PFS 4mo between 30% and 50%. Results: Forty-eight pts were enrolled: median age 64.5 years; 69% women; 27% gallbladder primary; 54% intra- and 19% extrahepatic. Ten pts came off study due to toxicity without disease progression before 4 mo on study and were replaced to evaluate the PFS 4mo endpoint. Of 38 evaluable pts, 18 pts (PFS 4mo 47%) were alive and progression-free at 4 mo, meeting the primary endpoint. With a median follow-up of 7.1 mo, median time to disease progression or study discontinuation due to toxicity for all pts was 2.3 mo (95% CI 1.8-4.6, PFS 4mo 38%), and for pts evaluable for the primary endpoint, median PFS was 3.5 mo (95% CI 1.8-5.5). Five pts (10%) had PFS beyond 12 mo. mOS for all pts was 7.9 mo (95% CI 5.7-11.7). Of 41 evaluable pts, the response rate was 2% (1 PR), and the disease control rate was 54%. Adverse events (AEs) were consistent with known toxicities from the FU/LV/nal-IRI regimen. Conclusions: FU/LV/nal-IRI is an effective second-line regimen for aBTC in US pts. There was significant early toxicity as 21% of pts came off study due to AEs before 4 mo. Correlative studies, including longitudinal analyses of circulating tumor DNA using banked blood specimens, are planned (NCT04005339). Clinical trial information: NCT04005339 .
Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
Hamilton, Erika P., Curigliano, G, M, Casado Martín, Lerebours, Florence, Tsurutani, Junji , Hu, Xichun, Aquino, Luciana Carla Martins de, O'Sullivan, Ciara Catherine, Tokunaga, Eriko , Okines, Alicia Frances Clare, Huang, Chiun-Sheng, Jacot, W, Sohn, J, Mueller, Volkmar, Viala, Helene, Tan, Qianwen, Feng, Wentao, Shen, Qi , Dieras, V, Curigliano, Giuseppe , Lerebours, Florence , Savard, Marie-France , Hu, Xichun , O’Sullivan, Ciara C. , Okines, Alicia , Jacot, William , Sohn, Joohyuk , Shen, Qi, Dièras, Véronique

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 1005-1005

10.1200/jco.2026.44.16_suppl.1005 Get It

1005 Background: In the phase 3 HER2CLIMB-05 study (NCT05132582), TUC + maintenance HP demonstrated a statistically significant improvement in progression-free survival (PFS) vs control treatment (Tx) (hazard ratio: 0.641, P < 0.0001) in patients (pts) with HER2+ locally advanced or metastatic breast cancer (MBC). Here we report additional efficacy and safety outcomes by stratified subgroups. Methods: Pts with centrally confirmed HER2+ MBC without evidence of progression following chemotherapy-based induction Tx (taxane + HP) were randomly assigned 1:1 to TUC (300 mg) or PBO BID + HP. Randomization was stratified by diagnosis ( de novo /recurrent), hormone receptor (HR) status (positive/negative), and presence or history of brain metastases (BM; yes/no). Endocrine therapy (ET) is permitted for pts with HR+ disease. The primary endpoint is investigator-assessed PFS. Confirmed objective response rate (cORR), duration of response (DOR), and safety were evaluated in stratified subgroups. Results: Among pts assigned to TUC + HP (n = 326) or PBO + HP (n = 328), ∼69% had de novo MBC, ∼53% had HR+ status with ∼45% having received concurrent ET, and ∼12% had baseline BM. At data cutoff (Sep 5, 2025), median PFS was longer with TUC than PBO + HP in all stratified subgroups; TUC + HP consistently improved cORR vs PBO + HP (Table). Safety outcomes in subgroups aligned with the overall population. Conclusions: TUC + HP demonstrated clinically meaningful efficacy vs PBO + HP in pts with de novo or recurrent disease, HR+ or HR− disease, and baseline BM or not, with no new safety signals identified. Results were consistent with the overall population and support TUC + HP as a potential new maintenance therapy across pts with HER2+ MBC. Clinical trial information: NCT05132582 . Efficacy outcomes. Overall De novo Recurrent HR+ (± ET) † HR− BM (yes) BM (no) TUC+HP(n=326) PBO+HP(n=328) TUC+HP(n=227) PBO+HP(n=226) TUC+HP(n=99) PBO+HP(n=102) TUC+HP(n=168) PBO+HP(n=176) TUC+HP(n=158) PBO+HP(n=152) TUC+HP(n=41) PBO+HP(n=40) TUC+HP(n=285) PBO+HP(n=288) Median PFS, mos (95% CI) 24.9(21.3−NE) 16.3(12.6−18.7) 28.9(22.7−NE) 16.8(12.9−19.2) 21.3(15.6−27.2) 12.7(8.3−18.1) 25.0(16.5−NE) 18.1(13.0−20.8) 24.9(19.4−NE) 12.6(9.4−16.8) 8.5(4.2−16.5) 4.2(2.2−8.1) 27.2(24.3−NE) 18.1(14.8−20.7) cORR*, % (95% CI) 22.6(18.0−27.8) 15.2(11.3−19.7) 26.1(20.2−32.7) 18.5(13.5−24.4) 15.1(8.5−24.0) 7.0(2.6−14.6) 20.1(14.0−27.5) 12.9(8.2−19.0) 25.2(18.4−33.0) 17.9(11.8−25.5) 15.0(5.7−29.8) 8.3(1.8−22.5) 23.8(18.7−29.5) 16.1(11.9−12.1) Median DOR*, mos (95% CI) 20.9(16.4−NE) 16.9(12.3−NE) NR(16.4−NE) 16.3(10.4−NE) 17.9(8.3−NE) NR(7.2−NE) 20.9(12.6−NE) 18.7(7.8−NE) NR(8.6−NE) 14.5(10.4−NE) 12.6(8.1−NE) 16.3(12.5−NE) 20.9(16.4−NE) 18.7(10.4−NE) *ORR and DOR were assessed in patients with target or non-target lesions at baseline. † Data on HR+ w/ ET will be presented.
LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis
Kotla, Sivareddy , Ko, Kyung Ae , Chen, Weiqing , Samanthapudi, Venkata Subrahman K, Hoang, Oanh, Mejia, Gilbert F. , Li, Shengyu , Lee, Hani , Zhang, Angie, Cho, Min Soon , Schadler, Keri L., Rivera, Luis Antonio, Samperio, Kay Carlene Tavares, Kim, Jung Hyun , Mendoza, Keila Carolina Ostos , Mariscal-Reyes, Karla N., Deswal, Anita, Fujiwara, Keigi , Koutroumpakis, Efstratios, Gi, Young Jin , Pathania, Rajneesh , Morrell, Craig N. , Lorenzi, Philip L. , Tan, Lin, Mahmud, Iqbal, Chini, Eduardo N., Herrmann, Joerg , Vasquez, Hernan G., Shen, Ying H. , Martin, James F. , Xu, Haodong, Le, Nhat‐Tu , Zhang, Aijun , Hoang, O.N. , Kim, Jung Hyun , Lee, Jonghae , Chen, Weiqing , Samanthapudi, Venkata Subrahmanya Kumar , Hoang, Oanh , Mejia, Gilbert , Li, Shengyu , Lee, Hani , Zhang, Aijun , Cho, Min Soon , Schadler, Keri , Rivera, Luis Antonio , Kim, Jung Hyun , Ostos-Mendoza, Keila C , Deswal, Anita M , Cooke, John P , Fujiwara, Keigi , Palaskas, Nicolas L , Koutroumpakis, Efstratios , Gi, Young Jin , Morrell, Craig , Lorenzi, Philip L , Madhmud, Iqbal , Hanssen, Nordin M J , Afshar-Kharghan, Vahid , Hamilton, Dale J , Yvan-Charvet, Laurent , Chini, Eduardo Nunes , Herrmann, Joerg , Shen, Ying H , Martin, James F , Seeley, Erin , Burks, Jared K , Brookes, Paul S , Wang, Guangyu , Le, Nhat-Tu , Abe, Jun-Ichi , Kotla, Sivareddy , Lee, Jonghae , Imanishi, Masaki , Cooke, John P. , Tan, Lin, Hamilton, Dale J. , Chini, Eduardo N. , Wang, Guangyu

Mayo Clinic

Circulation Research | May 27, 2026 | Volume: 139 | Issue: 2 | Pages: No page available

10.1161/circresaha.125.327427 | PMID 42200276 Get It

BACKGROUND: Atherothrombosis, which underlies most acute coronary syndromes and is driven by intraplaque thrombosis, preferentially occurs in regions of disturbed blood flow (d-flow). Although LATS1/2 (large tumor suppressor kinases 1 and 2) are known regulators of endothelial mechanotransduction, the mechanisms by which d-flow connects endothelial senescence, proliferation, and intraplaque thrombosis remain poorly understood. METHODS: We investigated endothelial cell (EC)-specific roles of Lats1/2 using inducible EC-specific knockout mice in a partial carotid ligation model. Spatial multiomics of human and mouse plaques was performed using imaging mass cytometry, COMET sequential immunofluorescence, and spatial metabolomics. RESULTS: Tamoxifen-induced deletion of both Lats1 and Lats2 (homozygous) in ECs caused fatal edema and increased vascular permeability. In contrast, Lats1 het ( ± ) / Lats2 homo ( −/−) -EC-specific knockout mice survived and developed spontaneous atherothrombotic plaques with neovascularization. Spatial proteomics revealed that LATS1/2 loss induced a senescence-associated stemness phenotype driven by CD38 upregulation. Spatial metabolomics showed sulfite and taurine accumulation, indicating SUOX (sulfite oxidase) deficiency. CD38 suppressed SUOX, demonstrated a switch into the reverse mode of mitochondrial complex V, increased succinate dehydrogenase activity, and promoted ATP consumption. Despite ATP depletion, glutamate metabolism and the citric acid cycle flux increased, sustaining EC proliferation under energetic stress. This senescence-associated stemness state promoted both proliferation and senescence, leading to fragile, leaky neovessels and intraplaque thrombotic lesions. Pharmacological CD38 inhibition attenuated these phenotypes. Similar EC states were observed in human plaques. CONCLUSIONS: Loss of Lats1/2 in ECs induces a CD38-associated senescence-associated stemness-like phenotype that promotes intraplaque thrombosis through mitochondrial metabolic reprogramming, including changes consistent with reverse-mode operation of mitochondrial complex V. These findings define a mechanistic link between disturbed flow, endothelial metabolic reprogramming, and intraplaque thrombosis and hemorrhage.
Long‐Term Outcomes of Leadless Pacemaker vs. Transvenous Pacemaker in End‐Stage Renal Disease
Agarwal, Siddharth, Patel, Harsh P., Patil, Shivaraj, Gupta, Anshul , Patel, Divya, Asad, Zain Ul Abideen, Munir, Muhammad Bilal , Sugrue, A M, Tan, Nicholas Y. , Munoz, Freddy Del‐Carpio, Cha, Yong‐Mei, Deshmukh, Abhishek, Gupta, Anshul R , DeSimone, Christopher V , Munir, Muhammad Bilal , Agarwal, Siddharth , Patel, Divya, Asad, Zain Ul Abideen , Sugrue, Alan , Munoz, Freddy Del‐Carpio , Cha, Yong‐Mei , DeSimone, Christopher V. , Deshmukh, Abhishek

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 26, 2026 | Volume: 37 | Issue: 7 | Pages: 1599-1604

10.1111/jce.70364 | PMID 42188975 Get It

ABSTRACT Background Patients with end‐stage renal disease (ESRD) undergoing dialysis have an increased risk of pacemaker‐related complications due to limited vascular access and increased susceptibility to infection. Leadless pacemakers (LPMs) may mitigate these risks compared with conventional transvenous pacemakers (TPMs), but long‐term comparative data in this population remain limited. Methods We conducted a retrospective cohort study using the TriNetX Research Network, including adults (≥ 18 years) with ESRD on dialysis who underwent LPM or TPM implantation between May 2016 and December 2020. Propensity score matching (1:1) was performed using demographics and comorbidities. Outcomes assessed over up to 5 years included all‐cause hospitalization, heart failure hospitalization, device re‐intervention, device‐related complications, infection‐related hospitalization, pacemaker‐induced cardiomyopathy, and all‐cause mortality. Results After matching, 901 patients were included in each group with well‐balanced baseline characteristics. LPM implantation was associated with a significantly lower risk of device re‐intervention compared with TPM (4.1% vs. 9.3%; hazard ratio [HR] 0.44; 95% confidence interval [CI] 0.28–0.69; p < 0.01). There were no significant differences between groups in all‐cause hospitalization (65.5% vs. 68.3%; p = 0.22), heart failure hospitalization (26.9% vs. 30.2%; p = 0.13), all‐cause mortality (37.5% vs. 35.3%; p = 0.34), device‐related complications (14.5% vs. 14.3%; p = 0.94), infection‐related hospitalization (1.6% vs. 2.1%; p = 0.35), or pacemaker‐induced cardiomyopathy (9.0% vs. 8.6%; p = 0.66). Conclusion In a large, propensity‐matched cohort of patients with ESRD on dialysis, LPMs were associated with fewer device re‐interventions and comparable long‐term clinical outcomes compared with TPMs.
Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure
Ibrahim, Ramzi, Dreher, Luke, Habib, E., Pham, Hoang Nhat, Ibrahim, Sammudeen , Bhakta, Mayurkumar, Sorajja, Dan , Shen, Win-Kuang, Scott, Luis R., Ayoub, C A, Arsanjani, R A, Masry, Hicham Z. El, Masry, Hicham El , Nabi, Hussein Abdul , Farina, Juan María, Tan, Min Choon , Noureldine, Hussein A , El Masry, Hicham Z, El Masry, Hicham , Ibrahim, Ramzi , Dreher, Luke , Farina, Juan M. , Pham, Hoang Nhat , Bhakta, Mayurkumar D. , Lee, Kwan , Scott, Luis R. , Arsanjani, Reza

Mayo Clinic

JAMA Network Open | May 26, 2026 | Volume: 9 | Issue: 5 | Pages: e2614674

10.1001/jamanetworkopen.2026.14674 | PMID 42189543 Get It

This cross-sectional study investigates the association between lipoprotein(a) levels and risk of ventricular arrhythmias among patients with heart failure with reduced ejection fraction receiving implantable cardioverter-defibrillator therapy.
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data
Gupta, Tulika Rudra, Polley, Mei‐Yin C. , Redd, Robert , Lee, Eudocia Q., Arrillaga‐Romany, Isabel , Tan, Yujue, Welch, Mary R., Galanis, E, Ahluwalia, Manmeet S., Colman, Howard , Nabors, L. Burt, Hepel, Jaroslaw, Elinzano, Heinrich, Chukwueke, Ugonma N., Beroukhim, Rameen, Nayak, L., McFaline-Figueroa, J. Ricardo, Batchelor, Tracy T. , Lu‐Emerson, Christine , Bi, W. L., Arnaout, Omar, Peruzzi, Pier Paolo, Haas-Kogan, Daphne, Aizer, Ayal , Doherty, Lisa, Chiocca, E Antonio, Reardon, David A. , Wen, Patrick Y. , Trippa, Lorenzo , Rahman, Rifaquat, Gilbert, Mark R. , Redd, Robert , Lee, Eudocia Q , Gilbert, Mark R , Touat, Mehdi , Welch, Mary R , Ahluwalia, Manmeet S , Colman, Howard , Nabors, Louis Burt , Schiff, David , Nayak, Lakshmi , Batchelor, Tracy T , Kaley, Thomas , Lu-Emerson, Christine , Mellinghoff, Ingo K , Peruzzi, Pier Paolo , Haas-Kogan, Daphne , Tanguturi, Shyam K , Aizer, Ayal , Chiocca, E Antonio , Reardon, David A , Ligon, Keith L , Weller, Michael , Mehta, Minesh P , Wen, Patrick Yung , Rahman, Rifaquat , Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Drappatz, Jan , Galanis, Evanthia , Ahluwalia, Manmeet S. , Nabors, Burt , Hepel, Jaroslaw T., Elinzano, Heinrich, Chukwueke, Ugonma , Nayak, Lakshmi , McFaline-Figueroa, J Ricardo , Mellinghoff, Ingo K. , Arnaout, Omar M. , Haas‐Kogan, Daphne A. , Doherty, Lisa, Santagata, Sandro , Meredith, David M. , Mehta, Minesh P. , Rahman, Rifaquat

Mayo Clinic

Journal of Clinical Oncology | May 22, 2026 | Volume: 44 | Issue: 21 | Pages: 2048-2058

10.1200/jco-25-01586 | PMID 42172567 Get It

PURPOSE Integrating external control data into clinical trial designs and analyses has the potential to accelerate drug development processes. We reanalyzed the three experimental arms of the Individual Screening Trial of Innovative Glioblastoma Therapy (INSIGhT), a randomized phase II platform trial in newly diagnosed O 6 -methylguanine-DNA methyltransferase-unmethylated glioblastoma (ClinicalTrials.gov identifier: NCT02977780 ). To evaluate the validity of using external data sets, we compared treatment effect estimates based on internal INSIGhT control data and matched external control data. METHODS The three experimental arms of INSIGhT (abemaciclib [n = 72], neratinib [n = 80], and CC-115 [n = 12]) did not improve survival compared with internal controls (standard chemoradiation [n = 70]). We derived external control patient-level data from multiple real-world and clinical trial data sets. We applied propensity score matching and Cox proportional hazards models to estimate treatment effects with external controls. Additionally, using this glioblastoma (GBM) data collection, we specified simulation scenarios to evaluate trial designs that integrate external controls. RESULTS After matching to external controls, no survival benefit was observed for patients receiving abemaciclib (hazard ratio [HR], 1.00 [95% CI, 0.75 to 1.34]), neratinib (HR, 0.93 [95% CI, 0.70 to 1.24]), or CC-115 (HR, 0.88 [95% CI, 0.41 to 1.88]). Simulations, together with the INSIGhT data and a collection of GBM data sets, allowed us to examine efficiencies and risks of clinical trial designs that leverage external control data. CONCLUSION The use of carefully matched external controls, to replace or augment the internal controls of INSIGhT, produced treatment effect estimates that were similar to previously published analyses. Single-arm trial designs and hybrid randomized designs incorporating propensity score–matched external control data evaluated treatment effects in the early-phase testing of experimental therapies in newly diagnosed GBM. The validity of this approach and risks of bias depended on the availability of comprehensive and accurate data on all potential confounders, in the absence of unmeasured confounding.
Common Medical Comorbidities, Demographic Factors and Levels of Plasma Biomarkers of Alzheimer’s Disease and Neurodegeneration in Black/African American Older Adults
Cid, Rosie E. Curiel, Ortega, Alexandra, Crenshaw, Kirsten, Vaccari, Juan Pablo de Rivero , Carrasquillo, Minerva M. , Zheng, D. Diane , Hinton, Dylan , Sfakianaki, Efrosyni, Crocco, Elizabeth A., Casellas, Heidi , Ramirez, Sofia, Abascal, Tan, Abel, Triana , Wang, Wei-En, Duara, Ranjan , Ertekin-Taner, Nilüfer, Loewenstein, David , de Rivero Vaccari, Juan Pablo , Zheng, D Diane , Hinton, Dylan , Casellas, Heidi , Kuchenbecker, Lindsey A. , Duara, Ranjan , Loewenstein, David , Carrasquillo, Minerva M. , Curiel, Rosie E. , Ortega, Alexandra , Crenshaw, Kirsten Horne , Vaillancourt, David E. , Crocco, Elizabeth , Ertekin‐Taner, Nilüfer

Mayo Clinic

Biomolecules | May 22, 2026 | Volume: 16 | Issue: 5 | Pages: 747

10.3390/biom16050747 | PMID 42194093 Get It

Emerging evidence suggests that systemic physiological factors may influence plasma biomarker concentrations of Alzheimer’s disease (AD) and related neurodegenerative processes, potentially affecting their specificity for central nervous system pathology. This study examined the relationship of demographic factors and medical comorbidities with plasma biomarkers of AD and neurodegeneration in a community-dwelling cohort of Black/African American (B/AA) older adults (N = 141). Participants underwent plasma assessment of phosphorylated tau at threonine 217 (p-Tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Results showed associations between plasma p-Tau217 and amyloid PET positivity, and significant intercorrelations among p-Tau217, GFAP, and NfL. Stepwise regression models incorporated demographics, amyloid PET status, and laboratory measures of renal, metabolic, and lipid function as predictors for each biomarker. p-Tau217 was primarily predicted by amyloid PET and renal function; GFAP by age and sex; and NfL by renal function, age, and sex. Findings indicate plasma biomarker concentrations in B/AA older adults reflect both central AD-related pathology and systemic physiological factors, particularly renal function, and demographic influences. Results underscore the importance of accounting for comorbid medical conditions and demographic characteristics when interpreting blood-based biomarkers and highlight the need for comprehensive medical phenotyping to improve diagnostic specificity and clinical utility.
Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
Tan, Jia Yi , Ng, Lay She , Nurliyanah, Atiqah, O'Leary, Daniel, Hilal, Talal , Hilal, Talal , Vignarajah, Aravinthan

Mayo Clinic

Leukemia & Lymphoma | May 22, 2026 | Volume: 67 | Issue: 9 | Pages: 1998-2001

10.1080/10428194.2026.2673104 | PMID 42169674 Get It